Acticor Biotech: rebound from the previous day's tumble

(CercleFinance.com) - Acticor Biotech posted a technical rebound on the Paris Bourse on Friday, after plummeting the previous day due to the failure of its Phase 2/3 trial in stroke treatment.


As mid-day approached, the biopharmaceutical company's share price had jumped 85%, a recovery so sharp that it led to an upward booking of the stock.

This rebound came after the stock had plunged by over 92% on Thursday, its clinical trial having failed to meet its evaluation criteria.

In a reaction note, analysts at Invest Securities refer to a valuation now simply reduced to net cash, i.e. a share price of between 0.17 and 0.23 euros.

As the company is a single-product, single-program company (...), the failure of the trial reduces the value of the clinical pipeline in its current state to zero", explains the brokerage firm.

Invest, which believes that further development of glenzocimab now seems unlikely, says it is considering three possible scenarios for Acticor's future.

These are, according to the intermediary, (1) a judicial liquidation for lack of activity and/or a buyer, (2) an M&A operation in the form of a merger between Erytech and Pherecydes and (3) a licensing agreement with the cash still available via the purchase of the rights to a new asset.

Copyright (c) 2024 CercleFinance.com. All rights reserved.